Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study
Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B. Schwarz, Etienne Sokal, Weibo Yang, Huimin Fan, Vyacheslav Morozov, Qing Mao, Hong Deng, Yang Huang, Lei Yang, Nicolas Frey, Clare Nasmyth‐Miller, Vedran Pavlovic, Cynthia Wat – 24 April 2018 – Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG‐B‐ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa‐2a treatment in children aged 3 to <18 years with CHB.